Victory Capital Management Inc. Purchases 23,638 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Victory Capital Management Inc. lifted its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 7.7% in the third quarter, according to its most recent filing with the SEC. The firm owned 331,809 shares of the company's stock after acquiring an additional 23,638 shares during the period. Victory Capital Management Inc. owned approximately 0.57% of Twist Bioscience worth $14,991,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Signaturefd LLC increased its position in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after purchasing an additional 306 shares in the last quarter. EdgeRock Capital LLC acquired a new stake in shares of Twist Bioscience during the 2nd quarter worth about $43,000. Blue Trust Inc. increased its position in shares of Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock worth $58,000 after purchasing an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in shares of Twist Bioscience during the 2nd quarter worth about $61,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock worth $98,000 after purchasing an additional 381 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research firms have weighed in on TWST. Robert W. Baird raised their price objective on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an "outperform" rating in a research report on Tuesday. Barclays lowered their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating for the company in a research report on Tuesday. JPMorgan Chase & Co. raised their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an "underweight" rating in a research report on Monday, August 5th. Scotiabank raised their price objective on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a "sector outperform" rating in a research report on Tuesday. Finally, Evercore ISI raised their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a research report on Tuesday, October 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $51.78.

Insider Buying and Selling

In other news, CAO Robert F. Werner sold 1,448 shares of the firm's stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $64,580.80. Following the sale, the chief accounting officer now directly owns 45,620 shares in the company, valued at approximately $2,034,652. This trade represents a 3.08 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Emily M. Leproust sold 14,334 shares of the firm's stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $639,296.40. Following the completion of the sale, the chief executive officer now owns 589,552 shares in the company, valued at approximately $26,294,019.20. The trade was a 2.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 98,118 shares of company stock valued at $4,391,151 over the last quarter. 3.92% of the stock is owned by company insiders.

Twist Bioscience Price Performance

TWST traded down $0.21 on Wednesday, hitting $41.11. 759,188 shares of the stock were exchanged, compared to its average volume of 952,883. Twist Bioscience Co. has a 12 month low of $23.07 and a 12 month high of $60.90. The business has a 50-day moving average of $43.93 and a two-hundred day moving average of $46.15. The firm has a market capitalization of $2.41 billion, a price-to-earnings ratio of -10.76 and a beta of 1.78.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.